CADLCandel Therapeutics, Inc.Running, no new patients
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Prostate Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 711 (planned)
- Started
- Sep 2011
- Main results expected
- Aug 2024
- Fully finished
- Dec 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.
Measured over: Assessed at each visit every 6 months through year 5 until event occurs.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-08-01, no fading
Raw record changes
- none yet
Trial ID NCT01436968 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC